Retension Pharmaceuticals (NASDAQ:RTSN) Stock Rated “Buy” in New Coverage at Guggenheim

Guggenheim assumed coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a report issued on Monday, MarketBeat.com reports. The firm issued a buy rating and a $55.00 price objective on the stock.

Retension Pharmaceuticals Price Performance

Shares of NASDAQ RTSN opened at $11.60 on Monday. Retension Pharmaceuticals has a twelve month low of $9.66 and a twelve month high of $18.64.

Insider Activity at Retension Pharmaceuticals

In other Retension Pharmaceuticals news, CEO Eric L. Keller bought 20,800 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, with a total value of $249,600.00. Following the acquisition, the chief executive officer owned 423,377 shares of the company’s stock, valued at $5,080,524. The trade was a 5.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Franklin M. Berger purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The stock was acquired at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the purchase, the director owned 10,000 shares in the company, valued at $120,000. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Retension Pharmaceuticals

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.